Cytokinetics Presents Additional 48-Week Data From FOREST-HC

SOUTH SAN FRANCISCO, Calif., April 05, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced additional 48-week data from FOREST-HCM (Follow-up, Open-Label, Research Evaluation of Sustained Treatment with Aficamten

Related Keywords

China , United States , Fadyi Malik , Diane Weiser , Clinical Trials Program For Aficamten , American College Of Cardiology , Youtube , Corporate Affairs , Exchange Commission , Research Development , Linkedin , Facebook , Us Food Drug Administration , Research Evaluation Of Sustained Treatment , National Medical Products Administration , Symphony Health , Cytokinetics Incorporated Nasdaq , Journal Of The American College Cardiology , Research Evaluation , Sustained Treatment , Annual American College , Scientific Session , Cytokinetic Executive Vice President , Broad Phase , Trials Program , Quantitative Understanding , Obstruction Impact , Exercise Capacity , Assessment Comparing Aficamten , Cardiac Endpoints In Adults , Breakthrough Therapy Designation , Drug Administration , Private Securities Litigation Reform Act , Safe Harbor , Vice President , Heart Failure , Claims Data Dof , Clinically Diagnosed Hypertrophic Cardiomyopathy , American College , American Heart Association Task Force , Region ,